Related references
Note: Only part of the references are listed.Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype
Milan J. Sonneveld et al.
ANTIVIRAL THERAPY (2012)
Long-Term Effect of Interferon Therapy in Patients with HBeAg Positive Chronic Hepatitis B Infection
Hakan Senturk et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
Michael J. Pencina et al.
STATISTICS IN MEDICINE (2011)
Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B
Jurrien G. P. Reijnders et al.
GASTROENTEROLOGY (2010)
Durability of Peginterferon alfa-2b Treatment at 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Vincent Wai-Sun Wong et al.
HEPATOLOGY (2010)
Early On-Treatment Prediction of Response to Peginterferon Alfa-2a for HBeAg-Negative Chronic Hepatitis B Using HBsAg and HBV DNA Levels
Vincent Rijckborst et al.
HEPATOLOGY (2010)
Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen Positive Chronic Hepatitis B Using On-Treatment Hepatitis B Surface Antigen Decline
Milan J. Sonneveld et al.
HEPATOLOGY (2010)
Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2009)
A Mechanism To Explain the Selection of the Hepatitis e Antigen-Negative Mutant during Chronic Hepatitis B Virus Infection
Lars Frelin et al.
JOURNAL OF VIROLOGY (2009)
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2008)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Michael W. Fried et al.
HEPATOLOGY (2008)
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
Giovanna Fattovich et al.
JOURNAL OF HEPATOLOGY (2008)
Drug therapy - Hepatitis B virus infection
Jules L. Dienstag
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years
G. Fattovich et al.
GUT (2008)
Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B
Chia-Ming Chu et al.
GASTROENTEROLOGY (2007)
Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
Jinlin Hou et al.
JOURNAL OF MEDICAL VIROLOGY (2007)
Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss
R. Bridget Ferns et al.
JOURNAL OF CLINICAL VIROLOGY (2007)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Prevalence of HBV precore/core promoter variants in the United States
CJ Chu et al.
HEPATOLOGY (2003)
Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants
M Hussain et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase
AB van Nunen et al.
GUT (2003)
Hepatitis B e antigen and the risk of hepatocellular carcinoma
HI Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation
SD Pas et al.
JOURNAL OF CLINICAL VIROLOGY (2002)
Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: Clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion
CM Chu et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B
A Erhardt et al.
HEPATOLOGY (2000)
Share Paper
